Triterras (NASDAQ:TRIT) and Clene (NASDAQ:CLNN) are both small-cap business services companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Volatility and Risk
Triterras has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Clene has a beta of -0.01, suggesting that its share price is 101% less volatile than the S&P 500.
62.6% of Clene shares are held by institutional investors. 44.3% of Triterras shares are held by insiders. Comparatively, 3.6% of Clene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares Triterras and Clene’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Triterras and Clene’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
This is a summary of current ratings and target prices for Triterras and Clene, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Triterras presently has a consensus price target of $17.50, indicating a potential upside of 141.38%. Clene has a consensus price target of $24.50, indicating a potential upside of 124.98%. Given Triterras’ higher probable upside, analysts clearly believe Triterras is more favorable than Clene.
Triterras beats Clene on 6 of the 9 factors compared between the two stocks.
Triterras, Inc. operates as a fintech company. It operates Kratos, a commodity trading and trade finance platforms that connects and enables commodity traders to trade and source capital from lenders directly online. The company is headquartered in Singapore.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic. Clene Inc. is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Triterras Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Triterras and related companies with MarketBeat.com's FREE daily email newsletter.